Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials

Nuvilex logo

SILVER SPRING, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX) ("Company"), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Inno Biologics Sdn. Bhd. to generate cell clones that are the basis of the Company's future Phase 3 cancer clinical trials.

Inno Biologics, a partner of Boehringer Ingelheim (one of the world's leading pharmaceutical companies headquartered in Europe), has state-of-the-art cGMP facilities that have been constructed to comply with regulations of both US FDA and European EMEA (the European regulatory authority equivalent to the FDA). Inno Biologics is in close geographic proximity to the Fisher BioServices storage facilities in Singapore and to Austrianova Singapore.

From clones generated by Inno Biologics, those with the highest enzyme activity that activates the cancer drug ifosfamide will be advanced through further testing. Eventually the best cell clones will be propagated and one will be prepared for encapsulation as part of the Company's treatment for advanced, inoperable pancreatic cancer as well as used to develop future treatments for other cancers.

Dr. Robert F. Ryan, Nuvilex's President and CEO commented "It is important to note we have selected an FDA recognized and cGMP compliant company to carry out the critical cell cloning portion of our overall developmental plan. Nuvilex will continue to employ the most stringent and prudent criteria in selecting entities to assist us in preparing for our future clinical trials."

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating the use of medical marijuana for oncology applications. For more information visit:

Safe Harbor Statement:

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692

Source:Nuvilex, Inc.